Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
British Journal of Dermatology · 24.05.2023 · 188 (6) · 740-748
DOI: 10.1093/bjd/ljad022 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, online erschienen am 30.03.2023. Verfasst von Andrew Blauvelt und 15 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Medical Research Center, Portland, OR, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 166-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Dermira, Eli Lilly and Company.
Abstract (Originalsprache)
Background
Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to interleukin (IL)-13.
Objectives
To evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) over 52 weeks of treatment in ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967).
Methods
Patients who responded to lebrikizumab 250 mg every 2 weeks (Q2W) at the end of the 16-week induction period were re-randomized 2 : 2 : 1 to receive lebrikizumab Q2W, lebrikizumab 250 mg every 4 weeks (Q4W) or placebo Q2W (lebrikizumab withdrawal) for 36 additional weeks. Response at week 16 was defined as achieving a 75% reduction in Eczema Area Severity Index (EASI 75) or an Investigator’s Global Assessment (IGA) of 0 or 1, with a ≥ 2-point improvement and no rescue medication use. Multiple imputation was used to handle missing data. Intermittent use of topical therapy was permitted during the maintenance period.
Results
After 52 weeks, an IGA of 0 or 1 with a ≥ 2 point improvement was maintained by 71.2% of patients treated with lebrikizumab Q2W, 76.9% of patients treated with lebrikizumab Q4W and 47.9% of patients in the lebrikizumab withdrawal arm. EASI 75 was maintained by 78.4% of patients treated with lebrikizumab Q2W, 81.7% of patients treated with lebrikizumab Q4W and 66.4% of patients in the lebrikizumab withdrawal arm at week 52. Across treatment arms, proportions of patients using any rescue therapy were 14.0% (ADvocate1) and 16.4% (ADvocate2). During the combined induction and maintenance periods of ADvocate1 and ADvocate2, 63.0% of lebrikizumab-treated patients reported any treatment emergent adverse event, with most events (93.1%) being mild or moderate in severity.
Conclusions
After a 16-week induction period with lebrikizumab Q2W, lebrikizumab Q2W and Q4W maintained similar improvement of the signs and symptoms of moderate-to-severe AD, with a safety profile consistent with previously published data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oregon Medical Research Center, Portland, OR, USA.
- Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
- Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- University Hospital Bonn, Bonn, Germany.
- Christine Kühne Center for Allergy Research and Education, Davos, Switzerland.
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
ORCID-Profile: Jonathan I Silverberg
Förderung
- Dermira
- Eli Lilly and Company
Zitieren
APA
Blauvelt, A., Thyssen, J. P., Guttman-Yassky, E., Bieber, T., Serra-Baldrich, E., Simpson, E., Rosmarin, D., Elmaraghy, H., Meskimen, E., Natalie, C. R., Liu, Z., Xu, C., Pierce, E., Morgan-Cox, M., Garcia Gil, E., & Silverberg, J. I. (2023). Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. British Journal of Dermatology, 188(6), 740-748. https://doi.org/10.1093/bjd/ljad022
Vancouver
Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. British Journal of Dermatology. 2023;188(6):740-748. doi:10.1093/bjd/ljad022
BibTeX
@article{Blauvelt2023,
author = {Blauvelt, Andrew and Thyssen, Jacob P and Guttman-Yassky, Emma and Bieber, Thomas and Serra-Baldrich, Esther and Simpson, Eric and Rosmarin, David and Elmaraghy, Hany and Meskimen, Eric and Natalie, Chitra R and Liu, Zhuqing and Xu, Chenjia and Pierce, Evangeline and Morgan-Cox, MaryAnn and Garcia Gil, Esther and Silverberg, Jonathan I},
title = {Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials},
journal = {British Journal of Dermatology},
year = {2023},
volume = {188},
number = {6},
pages = {740--748},
doi = {10.1093/bjd/ljad022}
}
EUVIMED